Merck Met Every Upgrade Condition We Set, and We Are Still on Hold: The Pipeline De-Risked, but a 60% Run and a Down Second Half Got There First

Results vs. Consensus

Merck reported before the open on Tuesday, August 4, with the call at 9:00 a.m. ET. The print beat on both lines, and both lines require unpacking, because the headline figure is a loss and the loss is not an operating event.

Year-over-Year Comparison (Q2'26 vs. Q2'25)

Sequential Comparison (Q2'26 vs. Q1'26)

Revenue. Five percent growth, four excluding currency, is a respectable number for a company this size and it beat a consensus that had been set conservatively. The composition is what matters. Oncology and the recent launches carried the quarter; the legacy franchises continued to erode on schedule. Diabetes fell 31%, Lagevrio has effectively gone to zero at $5M, and Vaxneuvance dropped 35%. What is new this quarter is that the single largest product line stopped contributing organic growth, a point we develop below.

Margins. Two consecutive quarters of gross-margin decline, now compounded by a full-point cut to the full-year assumption, is the quarter's clearest negative and it received almost no airtime on the call. The CFO's explanation was one sentence: "Gross margin was 81.1%, a decrease of 1.1 percentage points, primarily due to higher inventory reserves." Inventory reserves are a judgment line. Two quarters of them, plus a guidance cut, suggests something structural in the product or geographic mix rather than a single write-off, and management was not asked to elaborate.

EPS. The reported loss of $0.13 will be read as noise, and for modeling purposes it largely is. The more useful framing is that Merck is now running its second consecutive quarter in which the reported P&L is uninterpretable without a mental adjustment of several dollars per share. Full-year non-GAAP operating expense guidance now embeds $14.7B of one-time R&D charges across two acquisitions, and full-year non-GAAP EPS embeds $5.93 per share of them. A non-GAAP measure that requires its own set of adjustments to be meaningful has stopped doing the job non-GAAP measures exist to do.

Segment Performance

Geographic Split

The geographic split contains the quarter's most important single disclosure and it is buried in a supplemental table. U.S. base Keytruda fell 3% year over year. U.S. QLEX was $395M of the $463M global total. Add them and the U.S. franchise grew 5.4%, which is exactly the point: in Merck's largest and most profitable market, the flagship product is no longer growing on its own molecule. It is growing because patients are being moved to a differently-formulated version of the same molecule.

Oncology — Keytruda franchise

The franchise delivered $8,366M, up 5% nominal and 4% excluding currency, beating consensus by 3.7% and representing 50.4% of total company revenue. Growth was attributed to earlier-stage indications including triple-negative breast, cervical, head and neck and bladder cancer, plus higher metastatic demand in urothelial cancer. Welireg, Lynparza and Lenvima round out an oncology portfolio that continues to broaden.

Underneath that headline, the franchise's growth rate more than halved sequentially, from +12% in Q1 to +5% here, and the base molecule turned negative. The CFO addressed the trajectory directly in the forward-looking portion of the remarks rather than in the results discussion.

"We anticipate that total U.S. KEYTRUDA year-over-year growth will moderate as we increasingly reach peak penetration across several key indications. Additionally, as a reminder, we benefited by approximately $250 million due to the timing of wholesaler purchases in the third quarter of 2025, which will not repeat this year." — Caroline Litchfield, Chief Financial Officer

Assessment: Peak penetration is the polite phrase for a product that has run out of new patients to add faster than it loses old ones. That was always the pre-cliff sequence and it is not a surprise, but this is the first quarter in which it is visible in the reported numbers rather than in a projection. From here the franchise line is a function of two things we can measure: international expansion, still growing at 3%, and the pace of QLEX substitution. Neither is a growth driver in the ordinary sense. Both are defensive.

Oncology — Keytruda QLEX

The subcutaneous formulation delivered $463M, up from $128M in Q1, $35M in Q4 2025 and $5M in Q3 2025. That is 5.5% of the global franchise and, using the U.S.-only figures, 7.9% of the U.S. franchise. Because the product ramped through the quarter, the June exit rate is meaningfully above the full-quarter average. The permanent J-code took effect April 1, removing the reimbursement friction that had capped the launch.

"We have seen physician and patient adoption increase since the permanent J-code was established in April. As expected, early use has been predominantly in patients who are either on monotherapy or in combination with an oral agent. We remain confident in the trajectory of KEYTRUDA QLEX adoption." — Caroline Litchfield, Chief Financial Officer

Assessment: This is the single most consequential number in the report and it is tracking well. Merck's stated goal is 30% to 40% conversion by the end of 2027, and the trajectory from 1.6% to 5.5% of the global franchise in one quarter is consistent with getting there, provided the ramp does not stall when it moves beyond the easy monotherapy and oral-combination patients. That caveat is management's own and it is the right one: the harder half of the conversion is patients on intravenous combination regimens, where the infusion chair visit happens anyway and the convenience argument weakens. We would treat the next two quarters as the real test.

Cardiometabolic and Respiratory

Winrevair delivered $588M, up 75%, with the U.S. at $522M against $323M and international scaling from a small base as Japan and Europe launches progress. More than 1,800 new U.S. patients received a prescription in the quarter, and management flagged an increasing proportion of patients whose background therapy does not include a prostacyclin, which is the mix shift that supports the drug moving earlier in the treatment paradigm. Ohtuvayre, acquired with Verona in October 2025, contributed $204M, though management disclosed that the figure includes a specialty-pharmacy purchasing benefit that unwinds next quarter.

"Third quarter sales will be impacted by the unwind of specialty pharmacy purchases in the second quarter. We continue to invest behind our sales force and promotion to reach more physicians and patients in the U.S. We are also working with our specialty pharmacies to improve patient experience. We expect these actions to lead to accelerated growth in 2027." — Caroline Litchfield, Chief Financial Officer

Assessment: Winrevair is doing what a franchise-defining launch is supposed to do and it remains the cleanest bull argument in the portfolio outside oncology. Ohtuvayre is a different story: a $204M quarter that management pre-emptively discounted, with the growth case pushed out to 2027 and a candid acknowledgment that the specialty-pharmacy patient experience needs work. Buying a launch-stage asset and then spending a year fixing its channel is a familiar pattern and it is not free.

Vaccines

Gardasil returned to growth at $1,169M, up 4% nominal and 3% ex-FX, with international up 8% and the U.S. down 1%. That reverses a run of steep declines, though the year-to-date figure of $2,238M against $2,453M is still down 9%, and management attributed part of the international improvement to favorable tender timing in Europe rather than to underlying demand. Capvaxive grew 42% to $184M on international launches. Vaxneuvance fell 35% to $148M.

Assessment: Two things deserve attention here. First, the Gardasil stabilization is real but flattered: the comparison base was already depressed, and tender timing is not demand. We would not yet call the bear point resolved. Second, and more interesting, the pneumococcal franchise shrank. Capvaxive added $55M year over year while Vaxneuvance lost $81M, so the two products together delivered $332M against $358M, down 7%. Merck's newest vaccine is, on the current evidence, primarily cannibalizing Merck's previous vaccine. The press release presents the two products in separate lines and never nets them.

Animal Health

Animal Health delivered $1,775M, up 8% nominal and 5% ex-FX, with Livestock at $1,041M (+6% ex-FX) on ruminant and poultry demand and Companion Animal at $734M (+5% ex-FX) on new launches. Bravecto contributed $359M against $335M. The business also completed a bolt-on acquisition of TARGAN, adding high-speed biodevice technology to the commercial poultry portfolio.

Assessment: Unremarkable in the best sense. Animal Health continues to be the ballast in the story, growing mid-single digits ex-currency with no drama, no patent cliff and no regulatory overhang. It sequentially declined slightly, which is normal seasonality. Its strategic value rises as the pharmaceutical base approaches its transition, and the periodic speculation about a separation has gone quiet.

Key Topics & Management Commentary

Overall Management Tone: The most confident call of the three quarters we have covered, and the confidence was earned rather than asserted, resting on a dense run of clinical and regulatory wins that management could simply list. Roughly two-thirds of prepared-remarks airtime went to pipeline rather than results, which is itself a choice about where the equity story now lives. Analyst questioning was almost entirely scientific and forward-looking, with no meaningful pushback on the quarter's financial composition, the second consecutive gross-margin decline, or the implied second-half earnings trajectory.

1. The Keytruda Franchise Passed Its Inflection Point

Base intravenous Keytruda was $7,904M against $7,956M a year ago, a 1% global decline and a 3% U.S. decline. This is the first quarter in our coverage in which Merck's flagship shrank. The franchise line still grew 5%, because $463M of QLEX more than covered the gap, but the underlying molecule has stopped adding patients faster than it loses them.

The composition matters for the cliff arithmetic. Merck's 2028 loss-of-exclusivity math has always assumed a large base rolling down from a high level. If the base is already flat to declining more than two years ahead of the event, the peak from which the decline starts is lower than the models that were built on a still-growing franchise.

Assessment: Not alarming on its own, since substitution into QLEX is the intended mechanic and franchise dollars are what fund the company. But it removes an assumption that has quietly supported the bull case, namely that Keytruda would keep compounding into the cliff and give the pipeline more time. It will not. The transition has started.

2. QLEX Conversion Is Now the Entire Franchise Growth Story

QLEX moved from 1.6% of the global franchise to 5.5% in one quarter, and to 7.9% of the U.S. franchise. The permanent J-code effective April 1 removed the principal reimbursement obstacle, and adoption has concentrated where the convenience case is strongest, in monotherapy patients and those on oral combinations.

The economics of the conversion are the reason this matters more than the volume. A subcutaneous formulation with its own patent life carries the franchise past the intravenous molecule's exclusivity. Every point of conversion is a point of 2029 revenue that does not face generic pembrolizumab on the same date.

Assessment: On track, and this is the pillar that has strengthened most across our three quarters of coverage. The risk is not the current pace but the composition of the remaining opportunity. Getting from 8% to 35% requires converting patients on intravenous combination regimens who are going to the infusion centre regardless. Management has not yet described how that conversion happens, and it was not asked.

3. LIPFENDRA Is the Largest New Market Merck Has Opened in Years

The FDA approved LIPFENDRA (enlicitide) in July as the first and only once-daily oral PCSK9 inhibitor, based on CORALreef Lipids and CORALreef HeFH, with placebo-adjusted LDL-C reductions of 56% and 59% at week 24. Approval came months ahead of schedule through the FDA Commissioner's National Priority Voucher process. Regulatory reviews are under way in the European Union and China, and fixed-dose combinations with rosuvastatin and with an oral Lp(a) inhibitor are in development.

Management was explicit that this is a market-expansion play rather than a share-taking one, and equally explicit that the ramp will be slow.

"We do believe it's going to take time to get that access established. So we are expecting to see the pace not be as fast out of the gate, but with long term, continue to expect to see this to be definitely a blockbuster opportunity as we move forward." — Robert Davis, Chairman and Chief Executive Officer

Assessment: The commercial logic is sound and the addressable population is genuinely enormous. The constraint is that the label carries an LDL-lowering claim without a cardiovascular outcomes trial of its own, and the CVOT does not read out until 2029. Payers reimburse outcomes, primary-care physicians prescribe against guidelines, and the guidelines have moved in Merck's favour. But a 2029 CVOT means the revenue curve is back-loaded past the cliff, not into it. LIPFENDRA helps the 2030s story materially and the 2028-29 trough barely at all.

4. sac-TMT's First Phase 3 Win Validates the TROP2 Bet

TroFuse-005 met both primary endpoints, overall survival and progression-free survival, in advanced or recurrent endometrial cancer after platinum chemotherapy and anti-PD-1/L1 therapy. This is the first Phase 3 readout from a program comprising 17 ongoing global Phase 3 trials, developed with Kelun-Biotech. Merck plans to apply its National Priority Review Voucher to the endometrial filing. Partner data from OptiTROP-Lung05 and Lung06 in China add supporting evidence.

The strategic significance runs beyond one indication. Management described a deliberate split between first-mover indications, where sac-TMT can establish early leadership, and the large breast and lung opportunities, where it must be differentiated against competing TROP2 ADCs.

Assessment: A meaningful de-risking event, and it arrived a year ahead of the guided timeline. Endometrial cancer is not a large market, but a first Phase 3 win converts sac-TMT from a hypothesis into an asset and validates the linker-payload differentiation argument that underpins the rest of the 17-trial program. The lung and breast readouts remain the ones that determine whether this is a $1B product or a $5B one.

5. TL1A Delivered Two Wins and One Failure in the Same Quarter

Tulisokibart became the first anti-TL1A antibody to post positive Phase 3 results, meeting the primary endpoint of clinical remission in the ATLAS-UC induction-only study in moderately to severely active ulcerative colitis. A Phase 2 study in hidradenitis suppurativa met its primary and key secondary endpoints. A Phase 2 study in systemic sclerosis-associated interstitial lung disease missed its primary endpoint and will be discontinued.

The SSc-ILD failure matters because the immunofibrosis hypothesis is what justifies the breadth of the TL1A program. Management pushed back on reading it too widely.

"In relationship to SSc-ILD, I would just state, I would just step back. I don't know any anti-cytokine that has worked. So this was a bold move to move that forward. It's a challenging and refractory disease. We see no safety concerns." — Dean Li, President of Merck Research Laboratories

Assessment: The net is clearly positive: a first-in-class Phase 3 win plus a dermatology proof point against one failure in an indication where nothing has ever worked. The defence of the immunofibrosis thesis is reasonable but it is a defence, and the larger induction-and-maintenance study is what actually enables a filing. We score the pillar as repaired rather than proven.

6. Terns Is the Fourth Acquisition Since October

Merck completed the $6.8B acquisition of Terns Pharmaceuticals, taking a $5.7B charge and adding MK-4208, an oral allosteric BCR::ABL1 inhibitor in chronic myeloid leukemia with Breakthrough Therapy designation. This follows Verona in October 2025, Cidara in Q1 2026 and, within Animal Health this quarter, TARGAN. Full-year non-GAAP operating expense guidance now carries $14.7B of one-time R&D charges.

"Business development remains a high priority, and we maintain the ability within a strong investment-grade credit rating to pursue additional science-driven, value-creating transactions. We are on pace for approximately $3 billion in share repurchases this year, as previously communicated." — Caroline Litchfield, Chief Financial Officer

Assessment: Each deal is individually defensible on the science and none is large enough to threaten the balance sheet. The cadence is the issue, and it has accelerated rather than settled since we first flagged it last quarter. Net interest expense has already stepped up $236M year over year, and the buyback is being held flat at $3B while the acquisition spend compounds. Nothing here is a red flag. Everything here is a reason to verify capital-allocation discipline each quarter rather than assume it.

7. The Guide Went Up on Revenue and Down on Almost Everything Else

The revenue range was raised and narrowed to $66.3B–$67.3B. Every other line in the outlook moved unfavourably: gross margin from about 82% to about 81%, other expense from about $1.3B to about $1.4B, and the tax rate from 23.5%–24.5% to 35.0%–36.0%. The operating expense range moved from $36.0B–$36.8B to $42.0B–$42.7B, which is the Terns charge plus MK-4208 investment.

Assessment: The revenue raise is the headline and it is real, though the midpoint moved to roughly the Street number rather than above it. The gross-margin cut is the line to watch: a full point on $66.8B of revenue is roughly $670M of gross profit, which is larger than the revenue raise. On the composite, the operating outlook for the year is slightly worse than it was in May, not better.

8. The Implied Second Half Is a Down Half

This is the quarter's least-discussed and most important disclosure, and it is arithmetic rather than commentary. First-half non-GAAP EPS was -$1.41. The full-year midpoint is $2.71. The implied second half is therefore $4.12, against $4.63 in the second half of 2025, a decline of 11%. Since guidance assumes no further significant business development, that second half carries no acquisition charges.

The identified drivers are consistent with the number: the Ohtuvayre specialty-pharmacy unwind, the non-repeating $250M Keytruda wholesaler timing benefit from Q3 2025, moderating U.S. Keytruda growth, a full point of gross-margin compression, and roughly $0.12 per share of costs to finance Terns and advance MK-4208. Partly offsetting, other revenue is guided significantly higher on revenue hedging and an expected Q4 out-licensing milestone.

The revenue halves point the same way. First-half sales of $32,893M grew 5%; the guide midpoint implies about $33.9B in the second half against $33,676M, growth of under 1%.

Assessment: A raised revenue guide that implies approximately flat second-half sales and an 11% second-half earnings decline is not a contradiction, but it is a fact the headline obscures, and it went unchallenged on the call. It is also the cleanest single reason we are not upgrading into a 60% twelve-month run. The full-year underlying earnings picture, excluding both acquisition charges, is a midpoint of $8.64 against $8.98 in 2025. Merck is having an excellent pipeline year inside a flat-to-down earnings year.

9. The Flu Program Slipped a Season

MK-1406, the long-acting strain-agnostic influenza prophylactic acquired with Cidara for a $9.0B charge two quarters ago, will now run through a second Northern Hemisphere season. Southern Hemisphere enrolment is complete. Management framed the extension as strengthening the global regulatory package rather than responding to data, and reaffirmed a 2029 launch.

"I was also very clear that I did not need and would not take an interim. I did not take or saw an interim. I am going to maximize what this molecule can do in the time frame that I need to such that I do nothing to imperil the launch timing of 2029, but that I have the most robust label as well as robust real-world evidence that will be important for health authorities." — Dean Li, President of Merck Research Laboratories

Assessment: The explanation is coherent and the explicit statement that no interim analysis was performed is the right disclosure to make, because it forecloses the obvious suspicion. The chief executive's follow-on that this is "about strength of filing" and that the bridging study created the schedule slack is also fair. Still, an asset that cost $9.0B in charges is now a season further away with an added all-cause hospitalization endpoint, and the 2029 launch date sits on the far side of the cliff.

10. "A Hill, Not a Cliff" Gets Restated Without Modification

Asked directly about the shape of earnings through the loss-of-exclusivity period, the chief executive repeated the framing he has used all year, unchanged and with an added aspiration.

"We feel very good about the progress we're making with the over 20 products we have coming, $70 billion of commercial opportunity, and we've already started to see meaningful clinical derisking happening at a pace faster than we expected. So as we sit here today, we feel very good, as I've said in the past, we see that as the LOE period is more of a hill than a cliff. Nothing has changed in our view. I do think you're going to see a shallow dip with a fast return back to growth. And candidly, if we look at it on a non-risk-adjusted basis, we still aspire to grow through it." — Robert Davis, Chairman and Chief Executive Officer

Assessment: "Non-risk-adjusted" is carrying a great deal of weight in that sentence, and management uses the qualifier consistently, which is to its credit. The honest reading is that on a probability-weighted basis Merck still expects a dip. What has changed this quarter is not the framing but the evidence behind it: two 2027-guided readouts landing in 2026 makes the hill argument more credible than it was in May. It remains an argument, not a number, and management has still never quantified the trough.

11. Confidence Is Now Explicitly Higher Than in January

Asked what could derail the $70B opportunity and what had increased confidence, the chief executive declined to name a risk.

"So as we sit here today, my confidence is higher than it was in January because we are seeing meaningful derisking. As you recall, at that time, we said there were 10 programs that represented 70% of the $70 billion. And the fact that so many of those are already having positive data, so we are clinically derisking them, and we're seeing good launches of those that are underway, including an accelerated launch of LIPFENDRA by several months. It's hard to frankly point to anything I'm worried about. I'm actually feeling quite bullish across the board." — Robert Davis, Chairman and Chief Executive Officer

Assessment: This is the most bullish management has been in our coverage window, and the underlying facts largely support it. We would note only that a chief executive who cannot identify a single worry in response to a question explicitly asking for the biggest risk has answered half the question. The gross-margin trend, the U.S. Keytruda base turning negative, and a second-half earnings decline were all available answers.

Guidance & Outlook

The revenue raise represents growth of 2% to 4% against 2025's $65,011M, including roughly one percentage point of currency benefit at mid-July rates. The midpoint moved from $66.4B to $66.8B, an increase of $400M against a second-quarter revenue beat of $247M. The floor moved $500M and the ceiling only $300M, so the practical effect is to narrow the range around a modestly higher centre rather than to extend the top end.

The EPS guide requires the same adjustment as the quarterly figure. The midpoint fell $2.39, from $5.10 to $2.71, while newly-included Terns costs total $2.43 per share ($2.31 one-time plus roughly $0.12 to finance the transaction and advance MK-4208). Adding those back gives a like-for-like midpoint of $5.14, a $0.04 operational raise. Excluding both acquisition charges booked this year, Cidara at $3.62 and Terns at $2.31, the underlying full-year midpoint is $8.64 against 2025's reported $8.98.

Implied second-half ramp: first-half non-GAAP EPS was -$1.41, so the $2.71 midpoint implies $4.12 in the second half against $4.63 a year ago, a decline of 11%. Revenue tells a similar story once the halves are separated. The first half delivered $32,893M against $31,335M, growth of 5%. The guide midpoint implies about $33.9B in the second half against $33,676M a year ago, growth of under 1%, with the full guidance range spanning roughly -1% to +2%. Second-half revenue is guided to approximately flat and second-half earnings down 11%.

Street at: the revenue midpoint of $66.8B lands on approximately the Street's pre-print number rather than above it. Consensus EPS is not directly comparable because most published models had not incorporated the Terns charge, which was not in the prior outlook.

Guidance style: consistent with the pattern established over our coverage window. Merck sets an achievable initial range, beats modestly, and passes the beat through to the floor without raising the ceiling proportionally. The ceiling moved $300M while the floor moved $500M, which is a narrowing exercise more than a raise. The gross-margin cut, taken in the same breath, is the tell that the composite outlook is not improving as fast as the revenue line suggests.

Analyst Q&A Highlights

Whether sac-TMT Displaces the Company's Own Standard of Care in First-Line Lung

The opening question went straight to the most commercially loaded implication of the TROP2 data: whether Merck would run a trial putting its own next-generation ADC against the chemotherapy-plus-Keytruda regimen that currently defines first-line non-small cell lung cancer treatment. Management answered affirmatively and without hedging, and went further by naming an alternative checkpoint agent as a possible partner.

Q: "Dean, you previously stated a biomarker strategy would be the right approach for first-line NSCLC. But with sac-TMT, we've seen a signal regardless of PD-L1 expression with the OptiTROP-Lung05 and 06 data. What are the chances we could see a broad sac-TMT plus pembro trial that goes head-to-head against KEYNOTE-189? And is it fair to say we could see sac-TMT combos with both pembro and a PD-1/VEGF for first-line lung?"
— Akash Tewari, Jefferies

A: "My simple answer is yes on all accounts... So yes, we are going to rethink KEYNOTE-189, which is KEYTRUDA plus chemo. And now we have sac-TMT as an ADC as a next-gen chemo. I do think that we're going to be very thoughtful as to the IO agent and when we should use KEYTRUDA and when we should use other agents such as MK-2010."
— Dean Li, President of Merck Research Laboratories

Assessment: A striking answer, and more revealing than the questioner may have expected. Management is openly contemplating obsoleting its own first-line lung standard of care, and explicitly leaving open that the partner checkpoint inhibitor may not be Keytruda. That is the correct scientific posture and it is also an implicit acknowledgment that the franchise's defence runs through replacing it rather than extending it. Worth noting the willingness to say so on an open call.

Whether the TL1A Class Is More Than a Better Anti-TNF

A recurring line of questioning probed how much of the TL1A opportunity survives the systemic sclerosis failure, and whether the observed activity in dermatology exceeds what an established mechanism would already deliver. Management mapped the program across the three immunology segments and was candid that rheumatology remains unproven.

Q: "Dean, congrats on the HS trial update for the TL1A. I'm just trying to think out loud to what extent as we go into these new indications, is the activity we're seeing for these TL1As beyond what we would have expected from a TNF? I'm sure you can appreciate where I'm coming from on this."
— Umer Raffat, Evercore

A: "The TNFs have been really important drugs. They have been advanced. There is often problems with combining them because of their safety signal... I think the positive readout for HS gives us more confidence in the derm sort of possibilities for this drug... I still think that within the rheum space, which is, let's say, RA and to some degree, psoriatic arthritis, we'll have to sort of play that out as the data comes out."
— Dean Li, President of Merck Research Laboratories

Assessment: The differentiating claim is safety enabling combination therapy, not raw potency, which is a defensible and specific answer rather than a promotional one. It also implicitly concedes that single-agent superiority over established mechanisms is not the pitch. Given that competitors are pursuing combination approaches in inflammatory bowel disease aggressively, a clean safety profile is a genuine asset, but it is an enabling property rather than a differentiating outcome, and it will take combination data to monetize.

The Shape of Earnings Through the Loss of Exclusivity

The only question of the call directed at the financial trajectory rather than the science asked management to characterize the earnings profile through the 2028-to-early-2030s transition. The response restated the standing framing and added an aspiration, without engaging the specific request for the transition period's shape.

Q: "I guess with the pipeline derisking we've seen over the past year, can get any directional views or updated color on what you're envisioning Merck's earnings profile could look like as we move through the KEYTRUDA LOE? I know the focus of the company is more on the return to growth as we look out into the early 2030s. But just would be any thoughts on that transition period of earnings could look like over that, let's say, 2028 through early 2030s period."
— Christopher Schott, JPMorgan

A: "As we've said in the past, we feel very good about the progress we're making with the over 20 products we have coming, $70 billion of commercial opportunity... we see that as the LOE period is more of a hill than a cliff. Nothing has changed in our view. I do think you're going to see a shallow dip with a fast return back to growth. And candidly, if we look at it on a non-risk-adjusted basis, we still aspire to grow through it."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The question asked for the shape of the trough and received an adjective. "Shallow dip" is the most specific characterization management has offered, and it is still not a number, a duration, or a range. Three consecutive quarters of the same answer to the same question is now itself informative: either the internal number is not one management wants to publish, or the range of internal outcomes is too wide to publish. Neither reading argues for paying up for the transition.

LIPFENDRA Access, the Label, and the Missing Outcomes Trial

Two separate exchanges converged on the same commercial question: how quickly a first-in-class oral can secure reimbursement when its label carries an LDL-lowering claim and its own cardiovascular outcomes trial is years away. Management was notably realistic on pace and explicit about the trial timing.

Q: "It's another one on LIPFENDRA, please. Just the specific wording on the label, which talks about LDL reduction, but then that cardiovascular outcomes trials have shown to be, have shown that you get a reduction in LDL also leads to the reduction in events, specifically for monoclonal antibody PCSK9 inhibitors. So just wanted to check whether that wording is a help or a hindrance as you speak to payers and as you go about your promotion? And then still on this CVOT topic, what is the timing of your LIPFENDRA CVOT?"
— Multiple analysts incl. Luisa Hector, Berenberg; Geoffrey Meacham, Citi

A: "I think it's going to be extremely helpful. We believe that LIPFENDRA should be added on top of statins... We also know that the design principle, the design principles of LIPFENDRA, the agency understood was informed by the 2 antibodies out there. So I think that it could be helpful from a commercial standpoint... I should emphasize that we do not have CVOT right now, and we have an ongoing trial that will read out in 2029."
— Dean Li, President of Merck Research Laboratories

Assessment: The label language borrowing credibility from the antibody class outcomes data is a real commercial asset and management is right to flag it. But the 2029 CVOT readout is the number that matters for modelling. It means the steep part of the LIPFENDRA revenue curve sits beyond the exclusivity trough rather than inside it, and payer coverage before then rests on guidelines and LDL surrogacy rather than the company's own event data. Blockbuster eventually is entirely plausible. Blockbuster by 2029 is not the base case management is describing.

Market Expansion Versus Share Capture in PCSK9

A question on whether the opportunity lies in switching injectable patients or in treating the untreated drew the most quantitatively grounded commercial answer of the call, and a clear statement that the strategy does not depend on taking competitor share.

Q: "How do you guys think about the opportunity for injectable PCSK9 switch versus the bulk of the opportunity more in PCSK9 naive patients? And one thing that we've noticed is with injectable PCSK9 relative to statins is pretty low use in the primary care setting. So how do you see kind of the availability of now an oral when you say democratize access the sort of adoption dynamics in the primary care setting?"
— Jason Gerberry, Bank of America

A: "As we've said many times, we are not focusing this market on how do we take share from the injectable PCSK9. If you look today, injectables only reach about 5% or less of the total market. We're sitting today here in the United States with 30 million people receiving lipid-lowering therapies, but, who are not at their recommended LDL levels and who, even more who go untreated... So our goal is to expand, build the market, educate the market... this frankly, should raise the water for all boats and not be one where we're taking share."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The most convincing commercial answer given all quarter, because it is anchored in a specific and checkable market structure rather than an aspiration. If injectables reach under 5% of the treated population, the constraint on PCSK9 has been administration route rather than efficacy, and an oral genuinely changes the equation. The offsetting reality, which management acknowledged, is that market-building against physician inertia is slow and expensive work, and it shows up in SG&A well before it shows up in revenue.

Why the Influenza Program Added a Season

The most pointed question of the call asked whether the decision to extend the MK-1406 Phase 3 through another Northern Hemisphere season reflected something management had seen in the data. The response was an unusually direct denial that any interim analysis had occurred.

Q: "I have a question regarding the flu drug program, CD388. Can you talk a little bit about, like what were the reasons why you decided to add one more season of Northern Hemisphere here? And I think the big question here is that was this decision based on any data you have seen? Or is this just to satisfy the regulatory components rather than any confidence or lack of confidence in the data so far?"
— Mohit Bansal, Wells Fargo

A: "I was also very clear that I did not need and would not take an interim. I did not take or saw an interim. I am going to maximize what this molecule can do in the time frame that I need to such that I do nothing to imperil the launch timing of 2029, but that I have the most robust label as well as robust real-world evidence that will be important for health authorities."
— Dean Li, President of Merck Research Laboratories

Assessment: The right answer, delivered in the right form. An unambiguous statement that no interim was performed or reviewed is a falsifiable claim rather than a reassurance, and it removes the most damaging interpretation. The chief executive's addition that the schedule slack exists because a manufacturing bridging study was already on the critical path is corroborating detail rather than spin. We take management at its word here, while noting that a $9.0B charge has now bought an asset whose first revenue arrives after the cliff.

Competitive Positioning in PD-1/VEGF and Whether TL1A Can Stand Alone

The most competitively pointed question of the call came in two halves, both asking where Merck sits against rivals rather than against disease: how the bispecific program reads against a competitor's imminent Phase 3 data, and whether a single-agent TL1A can hold its own in inflammatory bowel disease while two large competitors push combination regimens. The answer was a strategy description rather than a claim of superiority, and it conceded the direction the field is moving.

Q: "Maybe for Dean, on the PD-1/VEGF bispecific program, just any updates on how the pace of that development is progressing and how you're thinking about any potential read across from Summit's HARMONi-3 data coming up?... So how you thinking about TL1A as a single agent in terms of its competitiveness versus these combo trials that J&J and AbbVie are aggressively pursuing?"
— Asad Haider, Goldman Sachs

A: "So we're going to focus our efforts on PD-1/VEGF in those 3 sort of Venn diagrams where we are uniquely able to move forward. We are very interested in following the Summit Akeso data. We think that, that's important data for us to follow... In relationship to combination, you're exactly right. The whole immunology field is trying to think about how it can go to combinations... So when we look at TL1A, we're looking to have one of the most effective, if not the most effective anti-cytokine in whatever the indication we have. But we think it's also very important to know that the safety profile is extremely clean, which then makes it possible to do combinations."
— Dean Li, President of Merck Research Laboratories

Assessment: Two useful admissions in one answer. On the bispecific, Merck is explicitly waiting on a competitor's data before committing, and is scoping its own effort to the overlap where it holds differentiated assets rather than competing head-on across the class. On TL1A, the competitive claim is a clean safety profile that enables combination, not single-agent superiority, which concedes that the destination in inflammatory bowel disease is combination therapy and that Merck is not yet there. Both are honest answers. Both also describe a fast-follower posture in two areas the $70B opportunity treats as core.

What They're NOT Saying

1. The U.S. Keytruda decline was never mentioned. Base intravenous Keytruda fell 3% in the U.S. and 1% globally. Neither figure appears in the prepared remarks, the press-release commentary, or any analyst question. It is disclosed only by subtraction, in a supplemental table splitting Keytruda from Keytruda QLEX. The franchise total was quoted throughout instead.
2. No quantification of the loss-of-exclusivity trough. For a third consecutive quarter, "a hill, not a cliff" and now "a shallow dip" are offered instead of a percentage, a dollar figure, or a duration. The one direct question on the earnings profile through 2028 to the early 2030s received the standing adjectives.
3. Gross margin got one sentence and no follow-up. Two consecutive quarters of decline plus a full-point cut to the full-year assumption were explained entirely by "higher inventory reserves." What is being reserved, in which products or geographies, and whether this is a one-off or a mix shift, went unasked and unanswered.
4. The implied second-half earnings decline was never framed as such. Management walked through each second-half headwind individually, the Ohtuvayre unwind, the $250M Keytruda comparison, moderating U.S. growth, but never aggregated them into the resulting $4.12 versus $4.63. The raised revenue guide was the headline instead.
5. Pneumococcal cannibalization goes unaddressed. Capvaxive's 42% growth is presented as a launch success. Vaxneuvance's 35% decline is attributed to "competitive pressure." That the two Merck vaccines net to a 7% franchise decline is not stated anywhere, and the press release keeps them in separate lines.
6. No detail on how QLEX converts the harder half. Adoption is acknowledged to be concentrated in monotherapy and oral-combination patients, which is the easy segment. Reaching 30% to 40% requires converting intravenous combination patients whose infusion visit occurs regardless. No mechanism was described.
7. Gardasil's tender timing was mentioned but not sized. International Gardasil grew 8% partly on "favorable timing of tenders in Europe." The magnitude of that timing benefit was not given, which makes it impossible to judge whether the franchise has genuinely stabilized or simply borrowed from a later quarter.
8. The 2029 CVOT was volunteered, its commercial implication was not. Management stated plainly that LIPFENDRA has no outcomes trial until 2029. What that means for payer coverage, and therefore for the revenue curve's position relative to the cliff, was left to the listener.

Market Reaction

• Pre-print setup: MRK closed at $127.77 on August 3, up 21.4% year to date against the S&P 500's 11.0%, and up 60.0% over twelve months. The stock entered the print roughly 3% below its 52-week closing high of $131.82, but down 1.4% over the trailing 30 days, having stalled just below that high for a month.
• Reaction session: the stock gapped up 0.5% to open at $128.46, traded as high as $129.99 (+1.7%) and as low as $126.22 (-1.2%), and closed at $128.00, up 0.2% or $0.23.
• Relative move: the S&P 500 rose 1.8% on the same session. MRK therefore lagged the index by roughly 1.6 percentage points on its own earnings day, after a revenue beat, an EPS beat and a raised revenue guide.
• Volume: 11.8M shares against a 30-day average of 10.2M, or 1.2x. Elevated but unremarkable.

A stock that opens up, extends to +1.7% intraday, and then closes flat while the market rallies nearly two percent has been distributed into. The intraday path is the story: buyers showed up for the headline beat and the pipeline list, and sellers met them just short of $130, still below the $131.82 closing high set earlier in the year.

The explanation is the setup rather than the print. After a 60% twelve-month advance, a 1.5% revenue beat and a $0.04 like-for-like guide raise are simply not enough new information to extend the move. Everything genuinely new in the quarter, the LIPFENDRA approval in July, the sac-TMT and tulisokibart readouts, the LITESPARK-022 and KEYNOTE-B15 approvals, had already been announced separately and traded on before August 4. The print itself contained no surprise, and what surprise it did contain, the gross-margin cut and the implied second-half decline, pointed the wrong way.

The month-long stall below the 52-week high preceding the print is the more useful signal. The market had already priced the pipeline news as it arrived and was waiting to see whether the financials would justify a further re-rating. On this evidence they did not, and the stock has now closed the gap to the average published sell-side target and trades slightly through it.

Street Perspective

Debate: Is the De-Risking Real, or Is the Market Right to Discount It?

Bull view: two readouts guided to 2027 landed in 2026, tulisokibart read out early, and LIPFENDRA was approved months ahead of schedule. Of the ten programs that represent roughly 70% of the $70B opportunity, several now carry positive Phase 3 data rather than hypotheses. The de-risking is measurable and it is accelerating.

Bear view: precedent is unambiguous. Markets do not pay for pipeline against a known mega-blockbuster expiry until post-cliff revenue is actually printing, and the discount typically widens rather than narrows as the date approaches. The skepticism is structural and no individual readout dissolves it.

Our take: the bulls have the better of the argument on facts and the bears have the better of it on timing. Both are right, which is why the stock is where it is. The de-risking is genuine, and it is also the case that a stock roughly 28 months from its principal patent expiry rarely earns multiple expansion, however good the pipeline news. We would rather own this story in 2028, at a trough multiple, with the conversion data in hand.

Debate: Has the Stock Run Ahead of the Fundamentals?

Bull view: at roughly 14.8x underlying earnings against a market near 22x, with a 2.7% growing dividend, MRK remains one of the cheapest quality franchises in large-cap healthcare. The re-rating from 12x simply corrects an unwarranted discount, and there is room toward the high teens as the pipeline proves out.

Bear view: a 60% twelve-month advance has repriced a business whose underlying earnings are flat this year and whose implied second half is down 11%. The stock now trades above the average published target, the easy valuation argument has been collected, and the next leg requires the cliff math to actually work.

Our take: the bears. Not because the multiple is demanding in absolute terms, it is not, but because the gap between price and our own fair value has closed. At $109 we were paid to wait. At $128, with underlying earnings flat and the second half guided down, we are paying roughly fair value for an outcome that does not resolve for two years.

Debate: Does QLEX Actually Solve the Cliff?

Bull view: conversion is running ahead of the pace required for the 30% to 40% goal by end-2027, the J-code obstacle is gone, and every converted patient is revenue that does not face generic pembrolizumab on the same date. This is the single highest-return defensive move available to the company and it is working.

Bear view: 7.9% U.S. penetration is the easy portion, drawn from monotherapy and oral-combination patients. The remaining conversion requires moving patients who are attending infusion appointments regardless, where the convenience argument largely disappears, and no mechanism for that has been described.

Our take: genuinely open, and it is the most important unresolved question in the story. The trajectory is encouraging and we have raised our assessment of this pillar accordingly. But the base intravenous molecule turning negative this quarter is a reminder that substitution and growth are different things. We want two more quarters of conversion data, specifically covering combination-regimen patients, before treating the cliff as materially defused.

Model Update Needed

Valuation impact: at $128.00, MRK trades at approximately 14.8x underlying 2026 earnings of $8.64 (excluding the Cidara and Terns one-time charges) and yields 2.7% on the $3.40 annualized dividend. That compares with roughly 12.5x when we last wrote at $109.18. We are raising our fair-value range to $120–138 from $108–125, representing 14x to 16x underlying earnings, to reflect a materially de-risked pipeline. The stock sits close to the midpoint of that range, implying a total return of roughly 3% including the dividend over the next twelve months. That is a market-like outcome and it is what a Hold describes.

Thesis Scorecard Post-Earnings

Overall: the thesis is stronger on the pipeline and weaker on the price. Bull #2 moves from at risk back to on track, which is the most significant single change in our three quarters of coverage and fully repairs the damage the LITESPARK-012 failure did last quarter. Bull #4 moves the other way, from on track to at risk, purely on valuation. Bear #2 has genuinely weakened. Bear #3 is confirmed and is now the operative constraint: this is a flat earnings year, and the guide implies a down second half. The pillars have rotated rather than netted, which produces the same rating for materially different reasons than last quarter.

Action: Maintain Hold. We set two conditions for an upgrade in May and the pipeline condition was met emphatically, so we owe an explicit account of why the rating is unchanged: the stock advanced 17% between the two reports and now trades at roughly fair value on our raised range rather than at a discount to our old one. We would upgrade on evidence that QLEX conversion extends into combination-regimen patients at a similar pace, or on a 2027 outlook that shows underlying earnings growth through the transition. We would downgrade on a Phase 3 reversal in the sac-TMT lung or breast program, a further leg down in gross margin, or an acquisition large enough to test the investment-grade rating.